[go: up one dir, main page]

CN120305277A - A kind of pet spray and preparation method thereof - Google Patents

A kind of pet spray and preparation method thereof Download PDF

Info

Publication number
CN120305277A
CN120305277A CN202510510279.6A CN202510510279A CN120305277A CN 120305277 A CN120305277 A CN 120305277A CN 202510510279 A CN202510510279 A CN 202510510279A CN 120305277 A CN120305277 A CN 120305277A
Authority
CN
China
Prior art keywords
parts
spray
chinese medicine
pets
traditional chinese
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510510279.6A
Other languages
Chinese (zh)
Inventor
杨丰利
孙静
刘雨双
喻俊皓
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yangtze University
Original Assignee
Yangtze University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yangtze University filed Critical Yangtze University
Priority to CN202510510279.6A priority Critical patent/CN120305277A/en
Priority to NL2040428A priority patent/NL2040428A/en
Publication of CN120305277A publication Critical patent/CN120305277A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明涉及一种宠物喷雾剂及其制备方法。该宠物用喷雾剂，其原料成分包括：中药组分、西药组分和pH缓冲液；按重量份数计，中药组分2～27份，其包括：茶多酚0.1～1份、绿原酸1～15份和薄荷脑0.1～1份；西药组分占1～15份，其包括：奥硝唑1～10份、林可霉素0.1～2份、糠酸莫米松0.1～0.5份、维生素B20.1～2份；pH缓冲液占58～96份。本发明的宠物用喷雾剂中含有中药组分、西药组分和缓冲液，能够充分发挥中药组分和西药组分之间协同作用，将其用于口腔疾病预防和治疗时，有效药物利用度高、效果好、不易产生耐药性。The present invention relates to a pet spray and a preparation method thereof. The raw material components of the pet spray include: a Chinese medicine component, a Western medicine component and a pH buffer solution; by weight, the Chinese medicine component accounts for 2 to 27 parts, including: 0.1 to 1 part of tea polyphenols, 1 to 15 parts of chlorogenic acid and 0.1 to 1 part of menthol; the Western medicine component accounts for 1 to 15 parts, including: 1 to 10 parts of ornidazole, 0.1 to 2 parts of lincomycin, 0.1 to 0.5 parts of mometasone furoate, and 0.1 to 2 parts of vitamin B2; the pH buffer solution accounts for 58 to 96 parts. The pet spray of the present invention contains Chinese medicine components, Western medicine components and a buffer solution, which can give full play to the synergistic effect between the Chinese medicine components and the Western medicine components. When it is used for the prevention and treatment of oral diseases, the effective drug utilization is high, the effect is good, and it is not easy to produce drug resistance.

Description

Spray for pets and preparation method thereof
Technical Field
The invention relates to the technical field of veterinary medicine preparation, in particular to a spray for pets and a preparation method thereof.
Background
In recent years, the number of household pets has increased significantly, and some pets have become one of the family members. However, due to various pathogenic factors and/or dietary effects, oral diseases such as canker sore, gingivitis, periodontitis, glossitis, dental calculus, halitosis, etc. of pets occur, and the feed intake of pets is reduced, emaciation, incomplete chewing, digestive system diseases, immunity decline, etc. are caused.
At present, the clinic treatment and prevention measures for oral diseases are limited, mainly tooth cleaning, oral antiviral drugs and oral antibacterial drugs, and certain effects are achieved. However, oral diseases belong to local diseases, and the oral systemic treatment has low effective drug utilization and large dosage, and meanwhile, after the oral antiviral and/or antibacterial drugs are treated until the infection is eliminated, the oral inflammation is often more difficult to treat than the infection, and in addition, the recurrence rate is high due to the improvement of virus variation, bacterial and fungal drug resistance, so that chronic infection is formed.
Therefore, from the perspective of traditional Chinese medicine, the development of the spray for the pets for preventing and treating the oral diseases of the pets has important significance.
Disclosure of Invention
In view of the above, it is necessary to provide a spray for pets and a preparation method thereof, which are used for solving the technical problems of low effective drug availability, poor effect and easy drug resistance of the existing oral disease prevention and treatment methods in the prior art.
The first aspect of the invention provides a spray for pets, which comprises the following raw materials in percentage by weight,
The traditional Chinese medicine comprises 2-27 parts of traditional Chinese medicine components, wherein the traditional Chinese medicine components comprise 0.1-1 part of tea polyphenol, 1-15 parts of chlorogenic acid and 0.1-1 part of menthol;
The western medicine comprises 1-15 parts of ornidazole, 0.1-2 parts of lincomycin, 0.1-0.5 part of mometasone furoate and 20.1-2 parts of vitamin B;
The pH buffer solution accounts for 58-96 parts.
Further, the traditional Chinese medicine composition accounts for 6-27 parts, the western medicine composition accounts for 1.5-14 parts, and the pH buffer solution accounts for 61-87 parts.
Further, the mass ratio of the traditional Chinese medicine components to the western medicine components is (0.4-4.5): 1.
Further, the mass ratio of chlorogenic acid to menthol is 1 (0.01-0.3).
Further, the pH of the spray for pets is controlled to be 6.5-7.5.
Further, the pH buffer is a phosphate buffer and/or a carbonate buffer.
Further, in the phosphate buffer solution, the mass fraction of the disodium hydrogen phosphate is 0.454-1.945 wt%, and the mass fraction of the sodium dihydrogen phosphate is 0.756-2.016 wt%.
The second aspect of the invention provides a preparation method of the spray for pets, which comprises the following steps of mixing the raw materials according to the proportion uniformly to obtain the solution spray for pets.
The drug effect functions of the main raw materials of the invention are as follows:
the tea polyphenol is a general name of polyphenol substances in tea, and the main components of the tea polyphenol comprise flavanones, anthocyanidins, flavonols, anthocyanidins, phenolic acid and dephenolic acid 6 compounds, and the tea polyphenol has various physiological activities of resisting oxidation, radiation, aging, blood fat, blood sugar and bacteria inhibiting and inhibiting enzymes, and the like, and has the effects of reducing blood pressure, blood coagulation, blood fat and obesity, preventing and treating cardiovascular diseases such as arteriosclerosis, thrombosis and the like, reducing blood sugar, preventing and treating diabetes, sterilizing and resisting viruses, preventing and treating diseases such as gastrointestinal tract, respiratory tract, influenza and the like, preventing and treating hepatitis, resisting aging and enhancing immune functions, strengthening teeth, preventing and treating periodontitis, preventing and treating dental caries, deodorizing and detoxifying and the like. In addition, tea polyphenols can also prevent damage to skin by solar rays.
Chlorogenic acid is one of the main antibacterial and antiviral effective pharmacological components of honeysuckle, has wide biological activity, and has the effects of resisting bacteria, resisting viruses, increasing white blood cells, protecting liver, promoting bile flow, resisting tumors, reducing blood pressure, reducing blood fat, scavenging free radicals, exciting the central nervous system and the like.
Menthol is the main component of peppermint and peppermint essential oil, is used as a stimulating agent in medicine, acts on skin or mucous membrane, has the effect of cooling and relieving itching, and can be used as a wind-dispelling agent for oral administration, and is used for treating headache, nose, throat inflammation and the like.
Ornidazole is used clinically in treating anaerobe, protozoa, trichomonas and other infections, and is used in treating various kinds of infectious diseases caused by susceptible anaerobes, such as bacteroides fragilis, bacteroides dirachta, bacteroides ovatus, bacteroides thetaiotaomicron, bacteroides vulgatus, clostridium, eubacterium, enterococcus and streptococcus, helicobacter pylori, bacteroides melanin, fusobacterium, CO 2 avium, gingivalis, etc. through the nitro radical in molecule, reduction to amino radical in anaerobic environment or through the formation of free radical, interaction with cell components and thus death of microbe.
Lincomycin belongs to lincomycin antibiotics, and is a 50S subunit acting on sensitive bacteria ribosomes, and can prevent peptide chain extension, thereby inhibiting protein synthesis of bacterial cells, and is commonly used for respiratory tract infection, skin soft tissue infection, female genital tract and pelvic cavity infection, abdominal cavity infection caused by anaerobic bacteria and the like caused by staphylococcus, streptococcus pyogenes, pneumococcus and anaerobic bacteria.
Mometasone furoate is a novel external and non-fluorinated glucocorticoid preparation which is a halogen-containing 'strong-effect' glucocorticoid preparation, does not cause systemic effect when being used for exerting local anti-inflammatory effect, has the characteristics of increasing action intensity and disproportionately increasing adverse reaction, and exerts stronger effects of resisting inflammation, resisting allergy, contracting blood vessels, reducing vascular permeability, reducing exudation, inhibiting cell division and the like after being combined with glucocorticoid receptor protein in cytoplasm after being absorbed by oral mucosa. But also can strengthen Th1 (helper T cell 1) response, inhibit Th2 (helper T cell 2) response, and balance the original unbalance of Th1/Th 2. Is not easy to cause adverse reactions such as oral mucosa atrophy or adrenocortical function inhibition, and is suitable for treating oral diseases effectively treated by corticosteroids.
Vitamin B2, also called riboflavin, is a component of the Huang Meilei prosthetic groups in the body (the yellow enzyme plays a role in hydrogen transfer in biological oxidation reduction), and when lacking, it affects the biological oxidation of the body, causing metabolic disorders, and the lesions are often manifested as inflammation of the parts of the mouth, eyes and external genitalia, such as stomatitis, cheilitis, glossitis, conjunctivitis and scrotitis.
Compared with the prior art, the invention has the beneficial effects that:
The spray for pets contains the traditional Chinese medicine components, the western medicine components and the buffer solution, can fully exert the synergistic effect between the traditional Chinese medicine components and the western medicine components, and has high effective medicine utilization rate, good effect and difficult generation of drug resistance when being used for preventing and treating oral diseases.
Detailed Description
The present invention will be described in further detail with reference to the following examples in order to make the objects, technical solutions and advantages of the present invention more apparent. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention.
The first aspect of the invention provides a spray for pets, which comprises the following raw materials in percentage by weight,
The traditional Chinese medicine comprises 2-27 parts of traditional Chinese medicine components, wherein the traditional Chinese medicine components comprise 0.1-1 part of tea polyphenol, 1-15 parts of chlorogenic acid and 0.1-1 part of menthol;
The western medicine comprises 1-15 parts of ornidazole, 0.1-2 parts of lincomycin, 0.1-0.5 part of mometasone furoate and 20.1-2 parts of vitamin B;
The pH buffer solution accounts for 58-96 parts.
According to the invention, western medicine components (such as tea polyphenol, chlorogenic acid and menthol) are adopted to prepare the spray for pets, so that the effects of treatment regulation and deodorization of the traditional Chinese medicine can be exerted, the broad-spectrum and powerful antibacterial, anti-inflammatory, antiallergic, vasoconstriction, vascular permeability reduction, exudation reduction, cell division inhibition and the like of the western medicine are exerted, the traditional Chinese medicine and the western medicine are mutually synergistic in the aspects of protecting gingiva and eliminating halitosis, the curative effect is enhanced, the mutual restriction in the aspect of immunosuppression of oral mucosa is realized, the local disease is treated locally, the toxic and side effects are reduced, and the spray can be effectively used for the treatment and prevention of the oral disease of pets and the drug resistance is not easy to generate. In the embodiment, preferably, the traditional Chinese medicine component accounts for 6-27 parts, the western medicine component accounts for 1.5-14 parts, and the pH buffer accounts for 61-87 parts. Further, the mass ratio of the traditional Chinese medicine components to the western medicine components is (0.4-4.5): 1. Within the range, the synergistic effect between the traditional Chinese medicine components and the western medicine components can be effectively exerted, and the obtained curative effect is better. Further, the ratio is (0.4 to 2.5): 1.
In the invention, chlorogenic acid and menthol can be compounded to cooperatively act on the cell membrane of the aerobic bacteria, so that the normal pH value inside and outside the cell is changed, and the aim of killing the aerobic bacteria is fulfilled. In this embodiment, the mass ratio of chlorogenic acid to menthol is 1 (0.01-0.3). Within this ratio range, the synergistic effect of the two can be better exerted. Preferably 1 (0.02-0.03), more preferably 1:0.03.
In the invention, the pH buffer solution has the function of controlling the pH of the spray for pets to be 6.5-7.5. Too high or too low pH can produce certain stimulation to enamel and gum, and too high pH can promote the generation of dental calculus, and too low pH can inhibit the growth of normal bacteria such as streptococcus salivarius in oral cavity, promote the proliferation of acidogenic bacteria and harmful bacteria, and aggravate dental caries. The specific kind of the buffer solution is not particularly limited, and a person skilled in the art can select a corresponding kind commonly used in the art and can play a corresponding role. For example, the buffer selected may be a phosphate buffer and/or a carbonate buffer. In some embodiments of the invention, the pH buffer is a phosphate buffer, and the phosphate buffer consists of disodium hydrogen phosphate, sodium dihydrogen phosphate, and water. Further, in the phosphate buffer solution, the mass fraction of the disodium hydrogen phosphate is 0.454-1.945 wt%, and the mass fraction of the sodium dihydrogen phosphate is 0.756-2.016%. The pH value of the phosphate buffer solution is 6.5-7.5 at room temperature.
The second aspect of the invention provides a preparation method of the spray for pets, which comprises the following steps of mixing the raw materials according to the proportion uniformly to obtain the solution spray for pets.
The preparation method of the spray for pets provided by the second aspect of the invention is used for obtaining the spray for pets provided by the first aspect of the invention.
In order to avoid redundancy, in each of the following examples and comparative examples, the phosphate buffer solution is selected to have a composition comprising 0.454-1.945 g of disodium hydrogen phosphate, 0.756-2.016 g of sodium dihydrogen phosphate and 96.0836-98 g of water per 100g of phosphate buffer solution. The pH value of the phosphate buffer solution is 6.5-7.5 at room temperature.
Example 1
The embodiment provides a spray for pets, which comprises the following raw materials:
Tea polyphenol 0.15g, chlorogenic acid 5g, menthol 0.15g, ornidazole 5g, lincomycin 0.6g, mometasone furoate 0.12g, vitamin B20.5 g and phosphate buffer 85.98g.
The embodiment also provides a preparation method of the spray for the pets, which comprises the following steps of mixing the raw materials according to the proportion, and sub-packaging the raw materials into spray bottles to obtain the solution type spray for the pets.
Examples 2 to 7 and comparative examples 1 to 7 differ from example 1 only in the raw material composition, and the raw material compositions of examples 1 to 7 and comparative examples 1 to 7 are summarized in tables 1 and 2.
TABLE 1
TABLE 2
Test example 1
Animal tests were carried out using the inventive examples 1-7, comparative examples 1-7 and 0.5% metronidazole solution.
Dogs 3255 with halitosis and stomatitis (vesicular, gingivitis, glossitis) were randomly assigned to 15 groups of 217 animals. 15 groups of animals were treated with oral spray using the inventive examples 1-7, comparative examples 1-7 and 0.5% metronidazole solution, respectively. All dogs had been treated once a day in the morning and evening. The therapeutic effect was observed after 14 days. The test results are shown in Table 3.
Determination criteria:
the cure is that the suffering dogs eat and chew normally, no pain (no salivation) exists, the ulcer surface disappears, the red swelling subsides, and the oral cavity has no special odor (halitosis);
is effective in improving or normalizing feeding and chewing actions of affected dogs, relieving or eliminating pain (salivation reduction), reducing or eliminating ulcer surface, relieving or eliminating red swelling, and relieving or eliminating special odor (halitosis) of oral cavity.
TABLE 3 Table 3
As can be seen from Table 3, the cure rate of the embodiments 1-7 of the invention for treating the oral diseases of the pets reaches more than 93%, the effective rate reaches more than 98%, and the cure rate is obviously superior to that of a control group which only adopts 0.5% of metronidazole solution, which shows that the embodiments 1-7 of the invention have good treatment effects for treating the oral diseases of the pets. Compared with example 1, the difference between example 6 and example 7 is only that the mass ratio of chlorogenic acid and menthol is different, which indicates that the mass ratio of chlorogenic acid and menthol has an important effect on the quality effect of oral diseases of pets, and that too high or too low is unfavorable for improving the treatment effect.
Compared with the example 1, the comparative example 1 is added with less traditional Chinese medicine components and more western medicine components, the comparative example 2 is added with more traditional Chinese medicine components and less western medicine components, and the cure rate and the effective rate of the oral diseases of pets are both poor, which indicates that the contents of the traditional Chinese medicine components and the western medicine components in the formula are required to be strictly controlled within a certain range, and the excessive or the too much of the contents are unfavorable for fully playing the synergistic effect of the traditional Chinese medicine components and the western medicine components.
Compared with the example 1, the comparative examples 3-7 are respectively not added with ornidazole, tea polyphenol, lincomycin, mometasone furoate and chlorogenic acid, which shows that only the content of the traditional Chinese medicine component and the western medicine component is limited in the range of the invention, the synergistic effect of the components can be fully exerted, the spray with good treatment effect on the oral diseases of pets can be obtained, and the lack of any component can not exert the synergistic effect with other components, thereby being unfavorable for improving the treatment effect.
Compared with the prior art, the invention has the beneficial effects that:
The spray for pets contains the traditional Chinese medicine components, the western medicine components and the buffer solution, can fully exert the synergistic effect between the traditional Chinese medicine components and the western medicine components, and has high effective medicine availability, good effect and difficult generation of drug resistance when being used for preventing and treating oral diseases;
The spray for pets can be used for treating and preventing oral diseases such as canker sore, gingivitis, periodontitis, glossitis, dental calculus, halitosis and the like of pets, and has the characteristics of oral deodorization, antibiosis, anti-inflammation, antiallergic, local disease local treatment, low production cost, good curative effect, high safety and good economic benefit.
The present invention is not limited to the above-mentioned embodiments, and any changes or substitutions that can be easily understood by those skilled in the art within the technical scope of the present invention are intended to be included in the scope of the present invention.

Claims (7)

1. A spray for pets is characterized by comprising the following raw material components of traditional Chinese medicine components, western medicine components and pH buffer solution in percentage by weight,
The traditional Chinese medicine comprises 2-27 parts of traditional Chinese medicine components, wherein the traditional Chinese medicine components comprise 0.1-1 part of tea polyphenol, 1-15 parts of chlorogenic acid and 0.1-1 part of menthol, and the mass ratio of the chlorogenic acid to the menthol is 1 (0.02-0.03);
The western medicine comprises 1-15 parts of ornidazole, 0.1-2 parts of lincomycin, 0.1-0.5 part of mometasone furoate and 20.1-2 parts of vitamin B;
The pH buffer solution accounts for 58-96 parts.
2. The spray for pets according to claim 1, wherein the traditional Chinese medicine composition accounts for 6-27 parts, the western medicine composition accounts for 1.5-14 parts, and the pH buffer accounts for 61-87 parts.
3. The spray for pets according to claim 1, wherein the mass ratio of the traditional Chinese medicine component to the western medicine component is (0.4-4.5): 1.
4. The pet spray according to claim 1, wherein the pH of the pet spray is controlled to be 6.5-7.5.
5. The pet spray of claim 1, wherein the pH buffer is a phosphate buffer and/or a carbonate buffer.
6. The pet spray of claim 5, wherein the phosphate buffer solution comprises 0.454-1.945 wt% of disodium hydrogen phosphate and 0.756-2.016 wt% of sodium dihydrogen phosphate.
7. The method for preparing the spray for pets according to any of claims 1 to 6, which is characterized by comprising the following steps of mixing the raw materials according to the proportion uniformly to obtain the solution type spray for pets.
CN202510510279.6A 2025-04-22 2025-04-22 A kind of pet spray and preparation method thereof Pending CN120305277A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202510510279.6A CN120305277A (en) 2025-04-22 2025-04-22 A kind of pet spray and preparation method thereof
NL2040428A NL2040428A (en) 2025-04-22 2025-05-23 A pet spray and its preparation method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202510510279.6A CN120305277A (en) 2025-04-22 2025-04-22 A kind of pet spray and preparation method thereof

Publications (1)

Publication Number Publication Date
CN120305277A true CN120305277A (en) 2025-07-15

Family

ID=96334050

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202510510279.6A Pending CN120305277A (en) 2025-04-22 2025-04-22 A kind of pet spray and preparation method thereof

Country Status (2)

Country Link
CN (1) CN120305277A (en)
NL (1) NL2040428A (en)

Also Published As

Publication number Publication date
NL2040428A (en) 2025-09-03

Similar Documents

Publication Publication Date Title
CN110151594B (en) Oral composition containing ectoin and hyaluronic acid and application thereof
CN1140264C (en) Chewing gum containing colloidal bismuth subcitrate
EP1959988B2 (en) Use of bovine lactoferrin for treating destructive inflammation of mucous membrane
CN100420432C (en) Mouthwash and preparation method
CN103083649B (en) Chewing gum for preventing and treating oral ulcer resulted from chemotherapy
CN101444555B (en) A kind of pure Chinese medicinal film for treating oral ulcer and preparation method thereof
CN102940595A (en) Mouthwash with functions of antibiosis, antiphlogosis and deodorization, and preparation method and use thereof
CN112121105B (en) Mouthwash spray for pets and preparation method thereof
CN106729649B (en) Oral care composition for treating xerostomia and application thereof
CN111110831B (en) Ulcer paste and preparation method thereof
CN103203011A (en) Chewing gum for preventing and treating oral ulcer after chemotherapy
CN120305277A (en) A kind of pet spray and preparation method thereof
CN111956682A (en) A butyrum-boron cream for treating stomatitis and gingivitis, and its preparation method and application
CN110787288A (en) Medical collagen oral ulcer protective gel and preparation method thereof
CN104906132B (en) A kind of plaster for preventing and treating lamb stomatitis
LU506947B1 (en) A pet mouthwash spray and its preparation method
CN106389962A (en) Traditional Chinese medicinal composition for preventing and treating lamb colibacillosis, and preparation method and application thereof
CN111329881A (en) A kind of oral ulcer film and its preparation method and application
CN108704056A (en) A kind of formula and its application method applied to odontopathy
CN104906131B (en) A kind of preparation method preventing and treating lamb stomatitis plaster
RU2838752C1 (en) Composition of dental agent possessing wound healing and anti-inflammatory activity
CN109568428B (en) Yongquan plaster for children
CN117797168A (en) Allergen-isolated nasal composition
CN106727621A (en) A kind of Western medicine powder for treating toothache
CN106620081A (en) Buccal tablet for treating oral ulcer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication